Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Efficacy and Safety of Brolucizumab vs Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema

Phase 3

Completed

Conditions: Diabetic Macular Edema

Interventions: Drug: Brolucizumab
Drug: Aflibercept

First Posted Date: 2019-04-17

Last Posted Date: 2022-08-12

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 517

Registration Number: NCT03917472

Locations: 🇸🇰
Novartis Investigative Site, Zvolen, Slovakia

COmparing arNi and Ace For Improving Erectile Dysfunction in mEN With reduCed Ejection Fraction Heart Failure

Phase 3

Completed

Conditions: Heart Failure
Erectile Dysfunction
Heart Failure, Systolic

Interventions: Drug: LCZ696
Drug: Enalapril matching placebo
Drug: LCZ696 matching placebo
Drug: Enalapril

First Posted Date: 2019-04-17

Last Posted Date: 2024-02-29

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 27

Registration Number: NCT03917459

Locations: 🇩🇪
Novartis Investigative Site, Wermsdorf, Germany

An Open-label Extension Study Evaluating Safety and Tolerability of LCZ696 in Subjects Who Completed PARAGON-HF in Japan.

Phase 3

Terminated

Conditions: Heart Failure With Preserved Ejection Fraction (HFpEF)

Interventions: Drug: LCZ696

First Posted Date: 2019-04-10

Last Posted Date: 2021-10-08

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 52

Registration Number: NCT03909295

Locations: 🇯🇵
Novartis Investigative Site, Shinagawa-ku, Tokyo, Japan

A Safety and Efficacy Study of Ligelizumab in the Treatment of CSU in Japanese Patients Inadequately Controlled With H1- Antihistamines

Phase 3

Completed

Conditions: Chronic Spontaneous Urticaria

Interventions: Biological: Ligelizumab

First Posted Date: 2019-04-09

Last Posted Date: 2025-03-06

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 66

Registration Number: NCT03907878

Locations: 🇯🇵
Novartis Investigative Site, Hiroshima, Japan

AScalate: Treat-to-target in Axial Spondyloarthritis

Phase 3

Completed

Conditions: Axial Spondyloarthritis

Interventions: Biological: Secukinumab/Adalimumab-Biosimilar
Other: Standard-of-care

First Posted Date: 2019-04-08

Last Posted Date: 2025-04-29

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 304

Registration Number: NCT03906136

Locations: 🇩🇪
Novartis Investigative Site, Ulm, Germany

Study of Safety and Efficacy of Multiple Doses of CFZ533 in Two Distinct Populations of Patients With Sjogren's Syndrome

Phase 2

Completed

Conditions: Sjögren Syndrome

Interventions: Drug: CFZ533
Other: Placebo

First Posted Date: 2019-04-05

Last Posted Date: 2023-09-15

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 273

Registration Number: NCT03905525

Locations: 🇬🇧
Novartis Investigative Site, Manchester, United Kingdom

Efficacy, Safety, Pharmacokinetics and Pharmacodynamics Study, Assessing Multiple LNP023 Doses in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria

Phase 2

Completed

Conditions: Paroxysmal Nocturnal Hemoglobinuria

Interventions: Drug: LNP023

First Posted Date: 2019-03-29

Last Posted Date: 2024-06-18

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 13

Registration Number: NCT03896152

Locations: 🇨🇳
Novartis Investigative Site, Taipei, Taiwan

Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors.

Phase 1

Active, not recruiting

Conditions: Nasopharyngeal Carcinoma
Microsatellite Stable Colorectal Cancer
Carcinoma, Non-Small-Cell Lung
Melanoma
Triple Negative Breast Cancer

Interventions: Drug: DKY709
Drug: PDR001

First Posted Date: 2019-03-27

Last Posted Date: 2025-05-04

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 98

Registration Number: NCT03891953

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Sarah Cannon Research Institute, Nashville, Tennessee, United States

and more 1 locations

Lipoprotein(a) in Patients With Cardiovascular Disease (CVD)

Not Applicable

Completed

Conditions: Cardiovascular Disease and Lipoprotein(a)

Interventions: Diagnostic Test: Blood draw for Lp(a)

First Posted Date: 2019-03-25

Last Posted Date: 2022-01-28

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 49001

Registration Number: NCT03887520

Locations: 🇻🇳
Novartis Investigative Site, Ho Chi Minh, Vietnam

Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients

Phase 2

Active, not recruiting

Conditions: B-Cell Acute Lymphoblastic Leukemia

Interventions: Biological: CTL019

First Posted Date: 2019-03-15

Last Posted Date: 2024-07-26

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 121

Registration Number: NCT03876769

Locations: 🇺🇸
Dana Farber Cancer Institute Dept.of DFCI, Boston, Massachusetts, United States
🇺🇸
Methodist Childrens Hospital ., San Antonio, Texas, United States
🇺🇸
City of Hope National Medical, Duarte, California, United States

and more 30 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy